Nootropics

Phenibut

A psychoactive substance associated with intoxication, dependence and withdrawal; FDA does not recognize it as a dietary ingredient.

Poison-center harm data; FDA ingredient finding

Also known as: fenibut · phenyl-GABA · PhGaba

Phenibut molecular structure — Structure reference · C10H13NO2

Practical use

Reviewed practical notes

Identify the substance: Check alternate names before treating a sleep or calm product as routine supplementation.
Describe exposure accurately: Keep the packaging and tell the treating team what was taken and what symptoms changed.
Avoid a homemade withdrawal plan: Regular use with possible dependence needs clinical assessment.

CDC poison-center report

FDA phenibut ingredient status

Overview

Phenibut appears in products marketed for calm, sleep or cognition. That marketing category should not be mistaken for ordinary nutrition or an approval to treat anxiety. FDA states that products declaring phenibut as a dietary ingredient are misbranded.

Risks and limitations

Poison-center reports include reduced consciousness, agitation and serious toxicity. Dependence and withdrawal are also reported. Severe confusion, breathing difficulty or inability to stay awake require emergency assessment; a product’s “supplement” branding does not lower that urgency.

How to read this

For someone already using phenibut repeatedly, a medically assessed withdrawal plan is more appropriate than an online self-directed schedule. Be explicit about all products and other substances involved when seeking help.

Research explained

US poison-center surveillance

Who was studied

1,320 phenibut-related exposure reports to US poison centers during 2009–2019.

What was found

Coma was reported in 80 cases, major effects in 12.6% and three deaths. Some serious outcomes occurred in reports involving phenibut alone.

What it cannot establish

These are selected reported exposures, sometimes involving other substances. They cannot estimate the chance of harm among all users or attribute every outcome solely to phenibut.

Read the original study

FDA’s finding concerns ingredient status

FDA states that phenibut does not meet the statutory definition of a dietary ingredient. This finding is narrower than a claim about every jurisdiction’s possession laws, and it does not establish an approved treatment for insomnia or anxiety.

Supporting source

Recognize the ingredient behind the name

FDA lists aliases including phenyl-GABA, phenibut HCl, fenibut and PhGaba. Reading the ingredient panel is more informative than assuming a relaxation product contains only familiar nutrients.